Literature DB >> 11986317

The effects of the Fanconi anemia zinc finger (FAZF) on cell cycle, apoptosis, and proliferation are differentiation stage-specific.

Mu-Shui Dai1, Nathalie Chevallier, Stacie Stone, Michael C Heinrich, Melanie McConnell, Tanja Reuter, Hal E Broxmeyer, Jonathan D Licht, Li Lu, Maureen E Hoatlin.   

Abstract

FAZF, a member of the BTB/POZ family of transcriptional repressor proteins, has been shown to bind to FANCC, the protein defective in patients with the bone marrow failure syndrome Fanconi anemia complementation group C. Because bone marrow failure in Fanconi anemia has been attributed to a failure of the hematopoietic stem cell population to produce sufficient progeny, we documented the expression of FAZF in human CD34(+) hematopoietic progenitor cells. FAZF was expressed at high levels in early stages of differentiation but declined during subsequent differentiation into erythroid and myeloid lineages. Consistent with its presumed role as a transcriptional repressor, FAZF was found in the nuclear compartment, where it resides in distinct nuclear speckles at or near sites of DNA replication. Using a FAZF-inducible myeloid cell line, we found that enforced expression of FAZF was accompanied by accumulation in the G(1) phase of the cell cycle followed later by apoptosis. These results suggest an essential role for FAZF during the proliferative stages of primitive hematopoietic progenitors, possibly acting in concert with (a subset of) the Fanconi anemia proteins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11986317     DOI: 10.1074/jbc.M201834200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  The BTB-ZF family of transcription factors: key regulators of lineage commitment and effector function development in the immune system.

Authors:  Aimee M Beaulieu; Derek B Sant'Angelo
Journal:  J Immunol       Date:  2011-09-15       Impact factor: 5.422

2.  ZBTB32 is an early repressor of the CIITA and MHC class II gene expression during B cell differentiation to plasma cells.

Authors:  Hye Suk Yoon; Christopher D Scharer; Parimal Majumder; Carl W Davis; Royce Butler; Wendy Zinzow-Kramer; Ioanna Skountzou; Dimitrios G Koutsonanos; Rafi Ahmed; Jeremy M Boss
Journal:  J Immunol       Date:  2012-07-30       Impact factor: 5.422

3.  Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression.

Authors:  Melanie J McConnell; Nathalie Chevallier; Windy Berkofsky-Fessler; Jena M Giltnane; Rupal B Malani; Louis M Staudt; Jonathan D Licht
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

4.  Disruption of PLZP in mice leads to increased T-lymphocyte proliferation, cytokine production, and altered hematopoietic stem cell homeostasis.

Authors:  Francesco Piazza; José A Costoya; Taha Merghoub; Robin M Hobbs; Pier Paolo Pandolfi
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

5.  Knock-down of Kaiso induces proliferation and blocks granulocytic differentiation in blast crisis of chronic myeloid leukemia.

Authors:  Jaime Cofre; João R L Menezes; Luciana Pizzatti; Eliana Abdelhay
Journal:  Cancer Cell Int       Date:  2012-06-18       Impact factor: 5.722

6.  Fanconi anemia proteins and their interacting partners: a molecular puzzle.

Authors:  Tagrid Kaddar; Madeleine Carreau
Journal:  Anemia       Date:  2012-03-29

7.  The promyelocytic leukemia zinc finger protein: two decades of molecular oncology.

Authors:  Bandar Ali Suliman; Dakang Xu; Bryan Raymond George Williams
Journal:  Front Oncol       Date:  2012-07-17       Impact factor: 6.244

8.  Tzfp represses the androgen receptor in mouse testis.

Authors:  Kari Furu; Arne Klungland
Journal:  PLoS One       Date:  2013-04-25       Impact factor: 3.240

9.  Novel Cul3 binding proteins function to remodel E3 ligase complexes.

Authors:  Wananit Wimuttisuk; Mark West; Brittney Davidge; Kebing Yu; Arthur Salomon; Jeffrey D Singer
Journal:  BMC Cell Biol       Date:  2014-07-10       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.